Dignify Therapeutics Receives $3.1 million in NIH Awards for Bladder, Bowel Therapy

RESEARCH TRIANGLE PARK, NC (RTP) – October 11, 2016 – Dignify Therapeutics LLC, a drug development company focused on restoring bladder and bowel control to people with spinal injury, spina bifida, and other neurological conditions, received three NIH SBIR/STTR grants in the third quarter totaling $3.1 million.  The grants were awarded by the National Institute of Neurological Diseases and Stroke, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute on Aging.  The grants support preclinical development of Dignify’s lead product, DTI-100, in preparation for a Phase I clinical study, as well as studies to identify 2nd generation compounds and alternative formulations, through a collaboration with the Division of Pharmacoengineering & Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy.

See the Full Article Here

This entry was posted in Chronic Spinal Cord Injury Research, spinal cord injury research and tagged . Bookmark the permalink.